Compare Prudential PLC (PUK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Sanofi SA — how do they compare? Prudential PLC trades at $23.87 (market cap $28.84B), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.3× Prudential PLC's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Sanofi SA for 94 Days on average.
| PUK | SNY | |
|---|---|---|
Market Cap | $28.84B | $95.18B |
Volume | 3,531,298 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $33.61 | $52.34 |
52-Week Low | $23.54 | $39.51 |
Typical Hold Time | 119 Days | 94 Days |
Enterprise Value | $28.38B | $114.48B |
Dividend Yield | 2.33% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
